Elmind Capital LP Acquires Shares of 70,000 Supernus Pharmaceuticals, Inc. $SUPN

Elmind Capital LP acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 70,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,255,700,000. Supernus Pharmaceuticals accounts for about 0.8% of Elmind Capital LP’s investment portfolio, making the stock its 25th biggest position.

Other hedge funds also recently modified their holdings of the company. Royal Bank of Canada boosted its holdings in shares of Supernus Pharmaceuticals by 68.1% during the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock worth $382,000 after buying an additional 4,729 shares during the period. AQR Capital Management LLC lifted its position in Supernus Pharmaceuticals by 35.2% during the first quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock worth $2,791,000 after acquiring an additional 22,182 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Supernus Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock worth $978,000 after acquiring an additional 1,297 shares during the period. Millennium Management LLC grew its position in shares of Supernus Pharmaceuticals by 370.5% in the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock valued at $4,695,000 after purchasing an additional 112,886 shares during the last quarter. Finally, Empowered Funds LLC increased its stake in shares of Supernus Pharmaceuticals by 16.0% during the first quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock worth $1,573,000 after purchasing an additional 6,619 shares during the period.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN opened at $45.36 on Wednesday. The business’s 50 day simple moving average is $46.80 and its 200 day simple moving average is $48.78. Supernus Pharmaceuticals, Inc. has a 1 year low of $42.45 and a 1 year high of $59.68. The company has a market capitalization of $2.64 billion, a P/E ratio of -23.62, a P/E/G ratio of 0.83 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). The company had revenue of $219.06 million during the quarter, compared to analyst estimates of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. Supernus Pharmaceuticals’s revenue was up 32.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.40 earnings per share. On average, sell-side analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Cantor Fitzgerald boosted their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $62.83.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.